Skip to main content
Amany Keruakous, MD, Internal Medicine, Augusta, GA

Amany Keruakous MD

Hematology/Oncology


Physician

Join to View Full Profile
  • 1120 15th StAugusta, GA 30912

  • Phone+1 706-721-8623

  • Fax+1 706-721-1459

Dr. Keruakous is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Amany Keruakous is a healthcare provider specializing in Internal Medicine, with subspecialties in Hematology and Oncology, based in Augusta, GA. She completed her residency in Internal Medicine at the University of Toledo from 2015 to 2018, and is a graduate of the University of Alexandria Faculty of Medicine (Class of 2013). Dr. Keruakous has published multiple articles in renowned journals such as Hematology Reports, Hematology/Oncology and Stem Cell Therapy, Frontiers in Public Health, Bone Marrow Transplantation, and Cancers. Her work mostly revolves around leukemia, lymphoma, health care disparities, and molecular therapies like CAR T-cell therapy.

Education & Training

  • University of Toledo
    University of ToledoResidency, Internal Medicine, 2015 - 2018
  • University of Alexandria Faculty of Medicine
    University of Alexandria Faculty of MedicineClass of 2013

Certifications & Licensure

  • GA State Medical License
    GA State Medical License 2021 - 2026
  • OK State Medical License
    OK State Medical License 2018 - 2021
  • OH State Medical License
    OH State Medical License 2015 - 2018
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Lectures

  • Hypomethylating Agent Maintenance Therapy after Allogeneic Stem Cell Transplant Improves Transplant Outcome in High Risk Acute Myelogenous Leukemia 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • Clinical Challenges: FLT3 Inhibitors After Allo-Transplant in AML
    Clinical Challenges: FLT3 Inhibitors After Allo-Transplant in AMLJanuary 6th, 2022

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: